Your session is about to expire
← Back to Search
Varespladib for Snake Bites (BRAVIO Trial)
BRAVIO Trial Summary
This trial will study if an IV and oral drug combo can help people bitten by venomous snakes, and if it's safe and effective.
BRAVIO Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.BRAVIO Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have a history of chronic liver disease.I was bitten by a Russell's viper or krait in India.This criterion does not apply to me.I have had a stroke, bleeding in the brain, heart attack, or severe lung blood pressure.I was bitten by a snake and have moderate to severe muscle weakness.I have been bitten by a snake that may be venomous.I am 18 or older and was bitten by a venomous snake.I have kidney problems or chronic kidney disease.I have a genetic condition that affects my blood's ability to clot.I am currently taking or have recently taken blood thinners or drugs for irregular heartbeat.I was bitten by a venomous snake less than 5 hours ago and have symptoms affecting more than one part of my body.
- Group 1: Varespladib Intravenous Form (IV) + Varespladib Oral tablet (LY315920) + SOC
- Group 2: Placebo Intravenous (IV) + Placebo Oral + SOC
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the most comprehensive level of enrollment in this experiment?
"Ophirex Inc. seeks to enrol 110 qualified individuals for their clinical trial, which will be held in the Desert Regional Medical Center of Palm Springs, California and Antelope Valley Medical Centre of Rosamond Kentucky."
What potential risks do patients incur when taking Varespladib Intravenous Form (IV) + Varespladib Oral tablet (LY315920) + SOC?
"While there is minimal evidence of its efficacy, the safety profile of Varespladib IV in conjunction with SOC and oral tablets (LY315920) has been rated a 2 due to multiple rounds of data supporting its security."
Are there multiple locations conducting this research within the state?
"Those eligible for this clinical trial can be enrolled at Desert Regional Medical Center, Antelope Valley Medical Centre and Emergency Medicine University of Kentucky. Additionally, there are 6 more sites available to interested participants spread across the US."
Are there vacancies in this research endeavor for participants?
"Affirmative, the details on clinicaltrials.gov verify that this medical trial has commenced recruitment of participants. It was initially posted 30th May 2023 and latest updates were released 7th June 2021; aiming to have 110 individuals from 6 different sites join the study."
Share this study with friends
Copy Link
Messenger